Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $178 from $177 and keeps an Outperform rating on the shares following the Q4 report. The firm believes the company’s earnings visibility remains high given solid underlying healthcare utilization, market share gains, and solid mix.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $180 from $165 at Piper Sandler
- Quest Diagnostics Reports Strong Q4 Revenue Growth
- Quest Diagnostics price target raised to $182 from $172 at Truist
- Quest Diagnostics price target raised to $189 from $184 at Baird
- Quest Diagnostics price target raised to $175 from $168 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com